A low-dose paroxetine salt (7.5 mg/d) is the only nonhormonal pharmaceutical approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe menopausal VMS, with ...

Objective: To update and expand The North American Menopause Society’s evidence-based position on nonhormonal management of menopause-associated vasomotor symptoms (VMS), previously a portion of ...